The effects of high dose methylprednisolone on apoptosis in children with acute lymphoblastic leukemia

Clinical and Laboratory Haematology

Volumn 25, Issue 1, 2003, Pages 35-40

  Uçkan, Duygu ^a   Yetgin, S ^a   Cetin M ^a   Ozyurek E ^a   Okur, H ^a   Aslan, D ^a   Tuncer, M ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Acute lymphoblastic leukemia; Apoptosis; Fas; Fas ligand; High dose methylprednisolone; Steroids

Indexed keywords

ANTINEOPLASTIC AGENT; FAS ANTIGEN; FAS LIGAND; LIPOCORTIN 5; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNOL L; PROTEIN BCL 2; STEROID;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; BLAST CELL; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANTIGENS, CD95; APOPTOSIS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; FAS LIGAND PROTEIN; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MEMBRANE GLYCOPROTEINS; METHYLPREDNISOLONE; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0037328456     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2257.2003.00475.x     Document Type: Article

References (29)

1. Buzyn A., Petit F., Ostankovitch M., Figueiredo S., Varet B., Guillet JG., Ameisen JC. & Estaquier J. (1999) Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: a mechanism of tumor immune escape in leukemia patients. Blood 94, 3135-3140.
2. Costlow M.E., Pui C. & Dahl G.V. (1982) Glucocorticoid receptors in childhood acute lymphoblastic leukemia. Cancer Research 42, 4801-4806.
3. Coustan-Smith E., Kitanaka A., Pui C.H., McNinch L., Evans W.E., Raimondi S.C., Behm F.G., Arico M. & Campana D. (1996) Clinical relevance of bcl-2 over-expression in childhood acute lymphoblastic leukemia. Blood 87, 1140-1146.
4. DiGuiseppe J.A., LeBeau P., Augenbraun J. & Borowitz M.J. (1996) Multiparameter flow-cytometric analysis of bcl-2 and fas expression in normal and neoplastic hematopoiesis. American Journal of Clinical Pathology 106, 345-351.
5. Friesen C., Herr I., Krammer P.H. & Debatin K.M. (1996) Involvement of the CD95(APO-1/Fas) receptor/ligand system indrug-induced apoptosis in leukemia cells. Nature Medicine 2, 574-577.
6. Friesen C., Fulda S. & Debatin K.M. (1997) Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia 11, 1833-1841.
7. Friesen C., Fulda S. & Debatin KM. (1999) Cytotoxic drugs and the CD95 pathway. Leukemia 13, 1854-1858.
8. Findley HW, & Zhou M. (1999) The clinical significance of Fas expression in leukemia: questions and controversies. Leukemia 13, 147-149.
9. Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French LE., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J., Tschopp J. (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363-1366.
10. Hiçsönmez G., Özsoylu S., Onat N., Zamani V., Gümrük F. & Tuncer M. (1992) High dose methylprednisolone in resistant and relapsed children with acute lymphoblastic leukemia. Medical and Pediatric Oncology 22, 68.
11. Hiçsönmez G., Özsoylu., Onat N., Zamani V., Gmrk F. & Tuncer M. (1997) High dose methylprednisolone in the treatment of children with high risk lymphoblastic leukemia. European Journal of Hematology 58, 26-31.
12. Hill L.L., Ouhtit A., Loughlin S.M., Kripke M.L., Ananthaswamy H.N. & Owen-Schaub L.B. (1999) Fas ligand: a sensor for DNA damage critical in skin cancer etiology. Science 285, 898-900.
13. Houghton JA. (1999) Apoptosis and drug response. Current Opinion Oncology 11, 475-481.
14. Kamihira S., Yamada Y., Tomonaga M., Sugahara K. & Tsuruda K. (1999) Discrepant expression of membrane and soluble isoforms of Fas(CD95/APO-1) in adult T-cell leukemia: soluble Fas isoform is an independent risk factor for prognosis. British Journal of Haematology 107, 851-860.
15. Karawajew L., Wuchter C., Ruppert V., Drexler H., Gruss HJ., Dorken B. & Ludwig W.D. (1997) Differential expression and function in T and B lineage acute lymphoblastic cells. Leukemia 11, 1245-1252.
16. Kaspers GJ., Pieters R. & Veerman A. (1997) Glucocorticoid resistance in childhood leukemia. International Journal of Pediatric Hematology and Oncology 4, 583-596.
17. McGahon AJ., Costa Pereira AP., Daly L. & Cotter TG. (1998) Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system. The British Journal of Haematology 101, 539-547.
18. Nagata S. (1994) Fas and Fas ligand: a death factor and its receptor. Advances in Immunology 57, 129.
19. O'Connell J., O'Sullivan G.C., Collins J.K. & Shanahan F. (1996) The Fas counter attack: Fas-mediated cell killing by colon cancer cells expressing Fas ligand. The Journal of Experimental Medicine 4, 1075-1082.
20. Rivera G.K., Raimondi S.C., Hancock M.L., Behm F.G., Pui C.H., Abromowitch M., Mirro J.J., Ochs J.S., Look A.T. & Williams D.L. (1991) Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet 339, 61-66.
21. Schuler D. & Szende B. (1997) Apoptosis and acute lymphocytic leukemia in children. Annals NY Acad Sciences 17, 28-37.
22. Smets L.A. & Van Den Berg J.D. (1996) Bcl-2 expression and glucocorticoid-induced apoptosis of leukemic and lymphoma cells. Leukemia & Lymphoma 20, 199-205.
23. Srivastava R.K., Sasaki C.Y., Hardwick J.M. and Longo D.L. (1999) Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. Journal of Experimental Medicine 90, 253-265.
24. Uckan D. (2000) Cancer cell and Fas ligand (CD95 ligand): immune escape or self-attack. Pediatric Pathology and Molecular Medicine 19, 223-234.
25. Xerri L., Devilard E., Hassoun J., Haddad P. & Birg F. (1997) Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis. Leukemia 11, 1868-1877.
26. Yang Y., Mercep M., Ware C.F. & Ashwell J.D. (1995) Fas and activation induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of fas ligand expression by retinoic acid and glucocorticoids. Journal of Experimental Medicine 181, 1673-1682.
27. Yarbro GS., Lippman ME., Johnson GE. & Leventhal BG. (1977) Glucocorticoid receptors in subpopulation of childhood acute lymphoblastic leukemia. Cancer Research 37, 2688-2695.
28. Yetgin S., Gürgey A., Tuncer M., Çetin M., Özbek N., Sayl T., Gler E., Kara A., Olcay L., Duru F., Gümrük F., Atahan L. Tunçbilek E. (1998) A Comparison of the effect of high-dose methylprednisolone with conventional-dose prednisolone in acute lymphoblastic leukemia patients with randomization. Leukemia Research 22, 485-493.
29. Yetgin S., Tuncer M.A., Çetin M., Gümrük F., Yenicesu., Tunç B., Öner A.F., Toksoy H., Koç A., Asian D., Özyürek E., Olcay L., Atahan L., Tunçbilek E & Gürgey A. (2003) Benefit of high-dose methylprednisolone in comparison to conventional dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-period follow-up. Leukemia 16, (in press).